HK1215441A1 - 人血清白蛋白結合化合物及其融合蛋白 - Google Patents

人血清白蛋白結合化合物及其融合蛋白

Info

Publication number
HK1215441A1
HK1215441A1 HK16103286.9A HK16103286A HK1215441A1 HK 1215441 A1 HK1215441 A1 HK 1215441A1 HK 16103286 A HK16103286 A HK 16103286A HK 1215441 A1 HK1215441 A1 HK 1215441A1
Authority
HK
Hong Kong
Prior art keywords
fusion proteins
serum albumin
human serum
albumin binding
binding compounds
Prior art date
Application number
HK16103286.9A
Other languages
English (en)
Inventor
Fabian Buller
Ulrich Wllner
Irene Zbinden
Isabella Attinger-Toller
Der Bey Ulrike Von
Susann Knig-Friedrich
Julian Bertschinger
Dragan Grabulovski
Patricia Henne
Original Assignee
Covagen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen Ag filed Critical Covagen Ag
Publication of HK1215441A1 publication Critical patent/HK1215441A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16103286.9A 2013-01-03 2016-03-21 人血清白蛋白結合化合物及其融合蛋白 HK1215441A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13150171.0A EP2752426A1 (en) 2013-01-03 2013-01-03 Human serum albumin binding compounds and fusion proteins thereof
PCT/EP2013/077227 WO2014106583A1 (en) 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof

Publications (1)

Publication Number Publication Date
HK1215441A1 true HK1215441A1 (zh) 2016-08-26

Family

ID=47458817

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103286.9A HK1215441A1 (zh) 2013-01-03 2016-03-21 人血清白蛋白結合化合物及其融合蛋白

Country Status (7)

Country Link
US (2) US9790475B2 (zh)
EP (2) EP2752426A1 (zh)
JP (1) JP2016508143A (zh)
AU (1) AU2013372004B2 (zh)
CA (1) CA2896962A1 (zh)
HK (1) HK1215441A1 (zh)
WO (1) WO2014106583A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925862A1 (en) 2013-10-01 2015-04-09 Glaxosmithkline Intellectual Property Development Limited Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
WO2018151868A2 (en) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
CN107353346A (zh) * 2017-08-09 2017-11-17 芜湖英特菲尔生物制品产业研究院有限公司 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
CN116284375A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
CA2865597A1 (en) * 2012-03-16 2013-09-19 Covagen Ag Novel binding molecules with antitumoral activity

Also Published As

Publication number Publication date
AU2013372004A1 (en) 2015-07-16
US9790475B2 (en) 2017-10-17
CA2896962A1 (en) 2014-07-10
WO2014106583A1 (en) 2014-07-10
US10364419B2 (en) 2019-07-30
EP2752426A1 (en) 2014-07-09
EP2941439A1 (en) 2015-11-11
AU2013372004B2 (en) 2017-05-25
US20190169581A1 (en) 2019-06-06
EP2941439B1 (en) 2018-01-31
JP2016508143A (ja) 2016-03-17
US20160076011A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
IL266715A (en) Fusion proteins containing binding sites for pdgf and vegf and methods of using them
HK1225641A1 (zh) Gitr抗原結合蛋白
HK1220466A1 (zh) 愛帕琳融合蛋白和其用途
HK1208476A1 (zh) 抗體、融合蛋白，及它們的使用方法
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
HK1217502A1 (zh) 結合蛋白及其應用
EP2950814A4 (en) PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
EP3019531A4 (en) Immunoglobulin fusion proteins and compositions thereof
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
HK1216159A1 (zh) 治療性融合蛋白
HK1215441A1 (zh) 人血清白蛋白結合化合物及其融合蛋白
HK1220903A1 (zh) 軟骨結合型融合蛋白
HK1231494A1 (zh) 殺蟲融合蛋白改進
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
WO2015057177A9 (en) Aptamers bound human serum albumin and glycated human serum albumin
GB201306588D0 (en) Peptides and Binding Partners Therefor
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof
AU2013901117A0 (en) CD43 binding proteins and uses thereof
AU2012901619A0 (en) Fusion Proteins and Use Thereof